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Perivascular nerve stimulation of rat livers perfused in situ with erythrocyte-free Kr bs-Henseleit buffer at constant pres- 
sure in a non-reci/'culating system resulted in an increase of glucose and lactate production and in a decrease of portal 
flow. Infusion of somatostatin in different concentrations (2 x 10 '7, 10 -8, 10 -9 mol.1-1 ) reduced the nerve-mediated activa- 
tion of glucose releasemaximally to 66%. There was only a slight effect on the lactate output, the nerve-mediated r uc- 
tion of portal flow was unaltered. In controls, somatostatin alone had no effect on the metabolic and hemodynamic pa- 
rameters. In order to differentiate between a presynaptic and postsynaptic mechanism, the noradrenaline overflow was 
calculated. The unaltered release of the neurotransmitter in the presence or absence of somatostatin excluded a presynap- 
tic mechanism. To mimic the nerve effects on the carbohydrate metabolism and on the hemodynamics, noradrenaline 
(2 x 10 -7. mol-1-1) was infused instead of the nerve stimulation over a period of 5 min. Somatostatin did not change the 
endocrine ffects of the eatecholamine under these conditions. The nerve-dependent ffect of somatostatin suggests hat 
other neurotransmitters ( .g. VIP) or mediators (e.g. prostanoids) may be influenced by somatostatin. 
Perfused liver; Noradrenaline; Somatostatin; Carbohydrate metabolism; (Rat, Hepatic nerve) 
1. INTRODUCTION 
The liver parenchyma is innervated by sym- 
pathetic and parasympathetic fibers of the 
autonomic nervous system [1]. Various metabolic 
pathways were reported to be regulated by the 
hepatic nerves [2-4]. In the in situ perfused rat 
liver electrical stimulation of the hepatic nerves 
around the hepatic artery and portal vein was 
shown to increase glucose and lactate output [5] as 
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well as urate and allantoin formation [6] and to 
reduce ketogenesis [7], urea release and ammonia 
uptake [8] as well as oxygen consumption [9,10]. 
The nerve action could be blocked by the a- 
blocking agent phentolamine and therefore, it was 
predominantly mediated by or-receptors [5]. The 
effects on the carbohydrate metabolism were 
reported to be modulated by insulin and glucagon 
[11]. Insulin inhibited the nerve-mediated activa- 
tion of glucose release in a dose-dependent man- 
ner, had no effects on the lactate output and the 
portal flow. Dependent on the hormone concentra- 
tion, the effects of glucagon and nerve stimulation 
on the glucose output were additive, on the lactate 
balance antagonistic. 
In vivo, the autonomic nerves interact with cir- 
culating hormones and mediators of hormone ef- 
fects. The investigations dealing with the 
interfering actions of hormones and nerves are 
supposed to show aspects of the in vivo situation. 
The interactions should not only be focused on the 
effects of the neurotransmitter, .g. noradrenaline 
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for the sympathetic nervous system, and the cir- 
culating hormones, but also on modulating effects 
of co-transmitters histochemically described in the 
liver parenchyma as VIP (vasoactive intestinal pep- 
tide) and neurotensin [12,13]. 
The present study shows that somatostatin 
modulates the nerve effects. Possible mechanisms 
of the hormone action were characterized. 
2. MATERIALS AND METHODS 
2.1. Materials 
All chemicals were reagent grade and from commercial 
sources. Enzymes and bovine serum albumin were purchased 
from Boehringer, D-6800 Mannheim. Synthetic cyclic 
somatostatin were from Serono, D-7800 Freiburg; L- 
noradrenaline from Sigma, D-8020 Taufkirchen. 
2.2. Animals 
Male Wistar rats 080-240  g body wt) were obtained from 
Versuchstieranstalt, D-3000 Hannover. They were kept on a 
12 h day-night rhythm with free access to food (standard iet 
1320 of Altromin, D-4937 Lage) and to water. 
2.3. Liver perfusion 
All experiments were started between 9 and 11 a.m. when the 
livers are still full of glycogen [14]. The rats were anaesthetized 
by intraperitoneal injection of pentobarbital (60 mg/kg body 
wt). Livers were perfused in situ with a medium containing a
Krebs-Henseleit-bicarbonate buffer equilibrated with 95°70 
(v/v) oxygen and 5070 (v/v) carbon dioxide. The perfusion 
pressure was constant at about 10 cm H20 with a flow rate of 
4 ml.  min-  1. g-  1 liver. 
2.4. Nerve stimulation and infusion of  noradrenaline 
The perivascular hepatic nerves were stimulated by a bipolar 
platinum electrode placed around the hepatic artery and portal 
vein (20 V, 20 Hz, 2 ms) for over 5 min. In order to mimic the 
nerve effects noradrenaline was infused in a concentration of 
2 × 10 -~ mol.1-1 over the same period. In different concentra- 
tions (10 -9, l0 -8, 2 × 10-Tmol. l -1),  the infusion of 
somatostatin was started 5 min before the onset of nerve 
stimulation or before the start of infusion of noradrenaline over 
a period of 10 min. 
2.5. Determination of  metabolites and noradrenaline 
Glucose and lactate were determined by standard enzymatic 
techniques using glucose dehydrogenase and lactate 
dehydrogenase, glutamate-pyruvic transaminase, respectively. 
Noradrenaline was quantitated by electrochemical detection 
after separation with high-pressure liquid chromatography [15]. 
3. RESULTS 
Perivascular stimulation of the hepatic nerves 
over a period of 5 min resulted in an increase of 
glucose and lactate output reaching the maximum 
value after about 5 min. The portal flow was 
decreased to 70°70 after 2 min. During the nerve 
stimulation, the portal flow began to return to the 
prestimulation level (fig.lA). In the presence of 
somatostatin (2 x 10 -?  mol. l-X), nerve stimulation 
led to the activation of glucose release, however, to 
a minor extent (66070, area under the curve 
calculated). Somatostatin also reduced the increase 
of lactate output. Almost the same results were ob- 
tained for the glucose and lactate output in the 
presence of 10 -8 mol. l  -x somatostatin (fig.2). In- 
fusing a lower concentration of somatostatin 
(10 -9 mol. l  -x) the effects were less pronounced 
(fig.2). 
The diminution of the portal flow after nerve 
stimulation was not influenced by somatostatin ex- 
cluding a hemodynamic action of the hormone in 
this model. The data show that somatostatin 
modulates the nerve-mediated ffects on the car- 
bohydrate metabolism in a dose-dependent 
manner. 
Somatostatin acts either on the presynaptic or 
on the postsynaptic site of the nerve action. The 
presynaptic interaction of the nerve release and 
somatostatin was determined by measuring the 
noradrenaline overflow. The noradrenaline 
overflow was reported to be a good parameter for 
the quantification of noradrenaline released into 
the synaptic left [16]. The data show that the hor- 
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Fig.1. Increase of glucose and lactate output and decrease of 
portal flow after nerve stimulation (20 Hz, 20 V, 2 ms) over a 
period of 5 min in the perfused rat liver in the absence (A) and 
presence (B) of 2 x 10 -~ mol.1-1 somatostatin. The values 
given are means :l: SE of 7 and 6 experiments, respectively. 
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Fig.2. Increase of glucose (Glu) and' lactate (Lac) output (area 
calculated under the curve) and decrease of portal flow (Flow) 
after nerve stimulation over a period of 5 min in the perfused 
rat liver in the absence and presence of somatostatin (SS) at 
different concentrations (2 × 10 -7, 10 -8, 10 -9 mo1.1-1). Values 
are means + SE of 7, 6, 5 and 3, respectively. Asterisks denote 
significant differences (*p < 0.05, **p < 0.005) as compared 
to the control group. 
mone did not change the noradrenaline overflow 
(table 1) and therefore xclude a presynaptic effect 
o f  somatostatin. 
Previous studies [5] demonstrated that the nerve 
effects on the carbohydrate metabolism and the 
Table 1 
The maximum noradrenaline overflow in the outflow after 
nerve stimulation in the perfused rat liver in the absence and 
presence of somatostatin (SS) 
Conditions Number of Noradrenaline 
experiments (pmol • min- 1. g- 1) 
Control 5 60.46 ± 15.40 
+ SS (2 >( 10 -7 mol-1 -t) 4 56.00 +_ 4.76 
+ SS (10 -s mol-1-1) 4 72.80 _+ 15.96 
Values are given as means ± SE 
Table 2 
Increase of glucose and lactate output and decrease of portal 
flow after infusion of noradrenaline (2x 10 -7 mo1-1-1) in the 
perfused rat liver in the absence and presence of somatostatin 
(ss) 
Infusion of Glucose Lactate 
~umol.min-l.g -t) (umol.min-t.g -1) 
Noradrenaline alone 1.21 + 0.16 0.48 ± 0.03 
Noradrenaline + SS 
(2 x 10 -7 M) 1.22 ± 0.11 0.44 ___ 0.04 
Values are given as means ± SE of 4 experiments, each 
hemodynamics could be mimicked by the infusion 
of  noradrenaline into the portal vein. The equipo- 
tent concentration was about 2 x 10 -7 mol.  1-1 [5]. 
In the absence or presence of  the high concentra- 
tion o f  somatostatin (2 x 10 -7 mol. l -1) ,  the 
metabolic changes on glucose and lactate output 
by infused noradrenaline did not significantly dif- 
fer (table 2). These results exclude an antagonism 
of  the neurotransmitter noradrenaline and 
somatostatin on the receptor/postreceptor level. 
4. D ISCUSSION 
In the present investigation it was shown that 
somatostatin modulated the nerve-mediated ac- 
tivation of  glucose release in the perfused rat liver. 
Somatostatin reduced the enhancement of  
hepatic glucose production without inhibiting the 
alteration of  portal flow. The basal glucose release 
of  the liver was not changed by the peptide. These 
effects are comparable to the action of  insulin. In- 
sulin was reported to inhibit the enhancement of  
glycogenolysis triggered by the hepatic nerves [11]. 
The effects of  somatostatin on the basal and 
hormone-st imulated glucose product ion of  the 
liver are discussed controversially. There are 
studies reporting no effect of  somatostatin on the 
carbohydrate metabolism in the perfused rat liver 
[17], rat liver slices [18] and isolated rat 
hepatocytes [19]. In contrast o these findings an 
inhibition of  glucagon-stimulated glycogenolysis 
was reported in the perfused liver [20] and isolated 
rat hepatocytes [21,22]. 
The physiological role of  circulating 
somatostat in is difficult to determine. Many ef- 
fects o f  the hormone were described using phar- 
macological doses in a range of  10 -7 mol . l  -~ 
[20-22]. In the portal vein plasma levels of  max- 
imal 500 pg/ml  were reported [23]. This cor- 
responds to about 2 x 10 -1° mol.1-1 taking into 
account hat somatostatin-14 and somatostatin-28 
are the two principal biologically active forms of  
the hormone.  However, the values given in the 
literature have to be critically interpreted because 
somatostatin i plasma is rapidly degraded. In the 
present study an effect of  somatostatin was observ- 
ed in the range of  10 -s mol.  I-1. This suggests that 
somatostatin is not active in a physiological range. 
However,  it is well known that isolated systems as 
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the perfused rat liver is less sensitive to hormone 
act ions than the in vivo organ. 
In the present study there was no antagonism 
between the glycogenolytic hormone noradrenal ine 
and somatostat in.  The mechanism of  nerve action 
is more complex than an interact ion of  two hor-  
mones.  Probably ,  the nerve ef fects  are mediated 
by interactions of  the nerve endings of  the 
neurons,  the non-parenchymal  cells and paren- 
chymal  cells [13,24]. The presynaptic site of  act ion 
was excluded by the determinat ion of the unaltered 
overf low of  noradrenal ine.  However,  a second 
transmitter  which is involved in the nervous regula- 
t ion of  hepatic carbohydrate  metabol ism could be 
inf luenced by somatostat in.  One candidate is V IP  
(vasoactive intestinal peptide) functioning as a 
neurotransmitter  specially in the gastrointest inal  
tract.  Anatomica l  studies demonstrated VIP  im- 
munohistochemical ly  in the liver [12]. V IP  was 
shown to activate the glycogenolysis in isolated 
hepatocytes.  The enhanced glucose product ion 
could be inhibited by somatostat in  [25]. Therefore,  
one may speculate that somatostat in  blocks the 
release of  V IP  acting as a co-transmitter  which 
reduces the nerve-mediated act ivat ion of  glucose 
output .  In the present study VIP was not detected 
in the outf low of  the perfused liver (data not 
shown). This could be due to a release of  V IP  after 
nerve st imulat ion too little to be detectable and/or  
to a rapid degradat ion in the synaptic cleft. 
Recently, it was shown that inhibitors of  the syn- 
thesis of  prostanoids reduced the nerve-mediated 
effects [13]. Prostaglandins were reported to be 
released after nerve st imulat ion [25]. These studies 
demonstrated the role o f  prostanoids ynthesized 
by non-parenchymal  cells in mediat ing the effects 
o f  hepatic nerves. In the present study one may 
suggest hat somatostat in  i terferes with the syn- 
thesis or release of  these mediators.  
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